NCT04362813 - Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia | Biotech Hunter

Enrollment

454

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

September 16, 2020

Study Completion Date

December 22, 2020

Conditions

Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Interventions

DRUG

Canakinumab

Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.

DRUG

Placebo

250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.

Trial Locations (39)

11219

Novartis Investigative Site, Brooklyn

19140

Novartis Investigative Site, Philadelphia

21201

Novartis Investigative Site, Baltimore

23298

Novartis Investigative Site, Richmond

24127

Novartis Investigative Site, Bergamo

27599

Novartis Investigative Site, Chapel Hill

28034

Novartis Investigative Site, Madrid

28040

Novartis Investigative Site, Madrid

28041

Novartis Investigative Site, Madrid

28702

Novartis Investigative Site, San Sebastián de los Reyes

31054

Novartis Investigative Site, Toulouse

35294

Novartis Investigative Site, Birmingham

44100

Novartis Investigative Site, Cona

60611

Novartis Investigative Site, Chicago

77030

Novartis Investigative Site, Houston

91206

Novartis Investigative Site, Glendale

94110

Novartis Investigative Site, San Francisco

94143

Novartis Investigative Site, San Francisco

98405

Novartis Investigative Site, Tacoma

111539

Novartis Investigative Site, Moscow

121309

Novartis Investigative Site, Moscow

123056

Novartis Investigative Site, Moscow

123182

Novartis Investigative Site, Moscow

193312

Novartis Investigative Site, Saint Petersburg

194354

Novartis Investigative Site, S-Petersburg

197022

Novartis Investigative Site, Saint Petersburg

197706

Novartis Investigative Site, Sestroretsk

390039

Novartis Investigative Site, Ryazan

656045

Novartis Investigative Site, Barnaul

02115

Novartis Investigative Site, Boston

02118

Novartis Investigative Site, Boston

44106-5000

Novartis Investigative Site, Cleveland

08907

Novartis Investigative Site, L'Hospitalet de Llobregat

08035

Novartis Investigative Site, Barcelona

EN5 3DJ

Novartis Investigative Site, Barnet

CV2 2DX

Novartis Investigative Site, Coventry

LS9 7TF

Novartis Investigative Site, Leeds

NW3 2QG

Novartis Investigative Site, London

SE5 9RS

Novartis Investigative Site, London